### M.J. Powers & Co. Continuing Education

### **PSYCHIATRY ALERTS NOS**

#### **Target Audience**

This activity is intended for physicians and other healthcare providers who are involved with or have an interest in the management of psychiatric disorders.

#### **Learning Objectives**

- Recognize and implement new diagnostic and treatment approaches for psychiatric disorders.
- Determine appropriate treatment selection for various psychiatric disorders.
- Identify and appropriately prescribe nonpharmacological therapeutic interventions for various psychiatric disorders.
- Determine appropriate patient evaluation and treatment selection for various psychiatric disorders.

#### Activity Code 18MP02N / Exam #14

Upon completing this activity as designed and achieving a passing score of 70% or higher on the posttest examination, participants will receive a letter of credit awarding *AMA PRA Category 1 Credit(s)*<sup>TM</sup> and the test answer key four (4) weeks after receipt of the post-test and registration/evaluation form.

#### Accreditation

M.J. Powers & Co. Publishers is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

M.J. Powers & Co. Publishers designates this enduring material for a maximum of 12 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### In order to obtain CME/CEU credit, participants are required to complete all of the following:

- 1. Read the learning objectives and review *Psychiatry Alerts NOS*, Volume X, July 2018 through December 2018 (6 issues), and complete the post-test.
- 2. Complete the enclosed registration/evaluation form and record your test answers in the boxes using either pen or pencil.
- 3. Mail the form to M.J. Powers & Co. Publishers, 45 Carey Ave, Ste 111, Butler, NJ 07405; scan and email it to cme@alertpubs.com; or fax it to 973-898-1201.

#### **Planning Committee**

Trish Elliott, Executive Editor, M.J. Powers & Co. Publishers, Butler, NJ Tara Hausmann, Associate Editor, M.J. Powers & Co. Publishers, Butler, NJ

#### **Contributing Editors**

Bennett Silver, MD, Private Practice, Springfield, NJ Kate Casano, MSHyg, M.J. Powers & Co. Publishers, Butler, NJ Donna Foehner, Assistant Editor, M.J. Powers & Co. Publishers, Butler, NJ

#### **Consulting Editor and CME Reviewer**

This activity was reviewed for relevance, accuracy of content, and balance of presentation by John C. Rose, MD, Private Practice, Bellevue, WA.

#### **Disclosure Declarations**

Kate Casano has no relevant financial relationships. Trish Elliott has no relevant financial relationships. Donna Foehner has no relevant financial relationships. Tara Hausmann has no relevant financial relationships. John C. Rose, MD has no relevant financial relationships. Bennett Silver, MD has no relevant financial relationships.

M.J. Powers & Co. Publishers is fully independent and accepts no commercial support of any kind.

#### **Off-Label Usage Disclosure**

This activity may discuss commercial products unlabeled for use or an investigational use of a product not yet approved by the United States Food and Drug Administration.

#### For Additional Information or Questions

M.J. Powers & Co. Publishers

Phone: (973) 898-1200 Email: cme@alertpubs.com

CME credit for this activity can be claimed through June 30, 2020.

# M.J. Powers & Co. Continuing Education

## **PSYCHIATRY ALERTS NOS**

1. In a controlled trial, the personalized real-time intervention for motivational enhancement (PRIME) smartphone app, designed to improve motivation, was not more effective than a waitlist control in adolescents and young adults with schizophrenia.  A. True B. False	5. Mantram therapy may appeal to some veterans because, in contrast to cognitive processing therapy and prolonged exposure therapy (the evidence-based psychotherapies currently used by the VA), it is:  A. Inexpensive B. Non-trauma focused C. Less time consuming D. All of the above
7/18, pgs. 37–38	7/18, pgs. 38–39
2. In the study, relative to controls, patients who received the PRIME intervention had larger increases in several components of the Trust Task, as well as significant improvement in secondary outcomes including defeatist beliefs, self-efficacy, and:  A. Hallucinations B. Persecutory delusions C. Depressive symptoms D. Pressured speech	6. Although a determination that mantram therapy is similarly effective to cognitive processing therapy or prolonged exposure therapy is premature based on these study results, the effect size for symptom reduction (0.49) observed in this study is generally similar to or greater than the effect sizes reported for these treatments.  A. True  B. False  7/18, pgs. 38–39
<ul> <li>3. Which of the following characterize motivational deficits in schizophrenia?</li> <li>A. They do not generally respond to traditional treatments</li> <li>B. They are crucial in determining outcomes</li> <li>C. They are best addressed early in the course of the disease</li> <li>D. All of the above</li> </ul>	7. According to a systematic review of psychoeducational interventions for bipolar disorder, there is considerable clinical trial support for psychoeducation.  A. Family B. Internet C. Group D. Both family and group
7/18, pgs. 37–38	7/18, pgs. 39–40
**************	
4. In a randomized trial of military veterans with PTSD, mantram repetition therapy, in which patients repeat a self-selected spiritually-related word or phrase, produced significantly greater improvement than present-centered therapy inrated symptoms post-treatment.  A. Clinician B. Patient C. Both clinician and patient	8. Studies of group psychoeducation showed reductions in symptom severity, affective episodes recurrence, the number and duration of hospitalizations, and bipolar disorder-associated stigma. In addition, and overall functioning were also positively impacted.  A. Medication adverse effects B. Somatic symptoms C. Family burden D. Treatment adherence
7/18, pgs. 38–39	7/18, pgs. 39–40

CME / Exam 14 1

\*\*\*\*\*\*

9. Therapies that target the mitochondria are of growing interest for the treatment of bipolar disorder. Several	14. The choice of the right parietal cortex as a treatment target in the study was based on its role in
already approved drugs for bipolar disorder, notably, improve mitochondrial function.	networks, which may bias attention toward threat-related stimuli. Functional MRI studies suggest these networks
A. Lithium	are abnormal in patients with GAD.
B. Valproic acid	A. Attention
C. Atypical antipsychotics	B. Learning
D. All of the above	C. Recognition
	D. All of the above
7/18, pg. 40	7/19 pag 41 42
10. Evidence to support the mitochondrial hypothesis of	7/18, pgs. 41–42
bipolar disorder includes an increased prevalence of mood	*********
disorders in patients with mitochondrial diseases, and	15. In a randomized trial of exposure and response
morphological abnormalities of mitochondria and	prevention (ERP) combined with cognitive therapy
abnormal energy metabolism in patients with bipolar	compared with a similar-intensity program of ERP alone
disorder.	in adult patients with obsessive-compulsive disorder,
A. True	combined treatment produced significantly greater
B. False	improvement on the subscale(s) of the Yale-
7/18, pg. 40	Brown Obsessive Compulsive Scale.
************	A. Obsessive only
	B. Compulsive only
11. The efficacy of standard CBT for hoarding disorder may be reduced by in older adults.	C. Both obsessive and compulsive 8/18, pgs. 43–44
A. Physical disability	0,10,783. 12 77
B. Presence of neurocognitive impairment	16. When study patients were classified by their predomi-
C. Low levels of social support	nant symptom subtype, those with the subtype
D. Family accommodation	responded preferentially to both treatments.
·	A. Contamination/washing
7/18, pgs. 40–41	B. Symmetry/ordering
12. In a randomized trial, Cognitive Rehabilitation and	C. Doubting-harming/checking
Exposure/Sorting Therapy (CREST), which targets the	D. None of the above
core symptoms of bipolar disorder and addresses	8/18, pgs. 43–44
neurocognitive weaknesses, was significantly more	******
effective than case management on measures of:	
A. Hoarding associated activities of daily living	17. In a preliminary study of patients with bipolar
B. Anxiety	disorder, imagery-focused cognitive therapy (ImCT)
C. Global illness severity	produced large improvements in:
D. All of the above	A. Depressive symptoms
7/18, pgs. 40–41	B. The number and duration of depressive episodes
*******	C. Anxiety
	D. All of the above
13. In a pilot study, repetitive transcranial magnetic stimulation (rTMS) of the right parietal cortex was not	8/18, pgs. 44–45
effective in a group of patients with comorbid generalized	18. Patients were not experiencing mania when referred
anxiety disorder (GAD) and insomnia.	for study participation, but scores on the Altman Self-
A. True	Rating Scale for Mania (ASRM) increased significantly
B. False	with ImCT, indicating emergent mania.
7/18, pgs. 41–42	A. True
1110, 1180. 71-72	B. False
	8/18, pgs. 44–45
	**************************************

2 CME / Exam 14

recently discharged patients with a psychotic or mood disorder, engaging with a peer recovery mentor (RM)	there is moderate support for the efficacy of cognitive behavioral therapy (CBT) and guided self-help in binge
effective in difficult-to-engage patients.	eating disorder. Both treatment modalities were effective
A. Is not at all	for most outcomes evaluated; however, neither treatment
B. Is always	was found to produce substantially greater decreases in
C. May be	than a wait-list control.
9/19 pag 45 46	A. Self-induced vomiting
8/18, pgs. 45–46	B. Comorbid depression
20. However, in the study nearly% of patients	C. Body mass index
assigned an RM never met with their mentor.	D. All of the above
A. 10	8/18, pg. 47
B. 30	
C. 50	25. Modest support for limited outcomes was also
D. 75	found for:
9/19 nos 45 46	A. Lisdexamfetamine
8/18, pgs. 45–46	B. Interpersonal therapy
21. In the study, compared with patients who received	C. SSRIs
standard care, those assigned to the RM condition who	D. All of the above
did interact with their peer mentor demonstrated less	8/18, pg. 47
severe drug problems during follow-up as well as greater	********
improvements in all of the following except:	
A. Social functioning	26. Despite a lack of clinical studies, the ketogenic diet
B. Self care	appears to be a promising intervention meriting research in mood disorders. The diet reduces body weight and can
C. Physical health	help control obesity, insulin resistance, and metabolic
D. Service satisfaction	syndrome, all of which are strongly correlated with
8/18, pgs. 45–46	in mood disorders.
******	A. Medication nonadherence
	B. Treatment resistance
22. According to a newly-developed model, information	C. Treatment engagement
obtained in an initial clinical interview can predict conver-	D. All of the above
sion to psychosis with nearly% accuracy in clinical high-risk patients.	8/18, pg. 48
•	0/10, pg. 40
A. 50	
B. 75	27. According to a post-hoc analysis of the intensive
C. 90	psychosocial treatment arm of the Systematic Treatment
D. 100	<b>Enhancement Program for Bipolar Disorder (STEP-BD)</b>
8/18, pgs. 46–47	study, patients with bipolar disorder who also have a
22 Th	current substance use disorder are likely to recover from depression within 1 year than patients
23. The new model includes items suspected to be particularly informative but traditionally not scored by other	without substance use problems.
research groups investigating conversion: violent ideation,	A. More
violent behavior, and auditory and visual perceptual	B. Less
abnormalities. All of these except were among the	
most consistent predictors of conversion.	9/18, pgs. 49–50
A. Auditory perceptual abnormalities	28. The study also found that patients with a past substance
B. Visual perceptual abnormalities	use disorder recovered more quickly than those without.
C. Violent behavior	A. True
D. Violent ideation	B. False
8/18, pgs. 46–47	
******	9/18, pgs. 49–50
	李宗帝李宗宗亦亦亦亦亦

CME / Exam 14 3

29. Among the risk factors for completed suicide in patients with bipolar disorder identified in a population-based cohort, was associated with the greatest risk.  A. Male gender B. Presence of a comorbid psychiatric disorder C. Criminal conviction in the previous year D. Previous suicide attempt	34. According to a longitudinal analysis of patients who received treatment for resistant depression, adjunctive vagus nerve stimulation (VNS) has positive effects on depression and quality of life. Compared with a control group who did not receive VNS, patients who did receive the adjunctive treatment demonstrated significantly greater improvement in quality of life beginning at and lasting through 5 years of follow-up.
9/18, pg. 50	A. 1 week
9/10, pg. 50	B. 1 month
	C. 3 months
30. However, when data were analyzed separately by	D. 6 months
gender, the factor with the greatest hazard ratio was	D. O Mondis
predictive only in men.	9/18, pgs. 51–52
A. True B. False	35. In the study, positive effects of VNS on quality of life were seen in patients with:
9/18, pg. 50	A. Unipolar or bipolar disorder
	B. Unipolar depression only
21 01 1 10 1 1 1 1 1 1	C. Bipolar depression only
31. Other significant risk factors for suicide in these patients included living alone and in the	, ,
previous year.	9/18, pgs. 51–52
A. Inpatient psychiatric care	***********
B. An affective or depressive episode	26 A Dutch ashort study of hislogical aging found
C. Involuntary psychiatric hospitalization	36. A Dutch cohort study of biological aging found patients with depression to have an estimated epigenetic
D. All of the above	age that was nearly older than a control group of
	patients with no psychiatric disorder.
9/18, pg. 50	A. 5 months
*********	B. 8 months
32. A randomized trial evaluated online interventions	C. 18 months
involving brief daily writing tasks in a group of adults	D. 2 years
with nonsuicidal self-injury (NSSI). Of the 3 interventions tested, produced significant reductions in NSSI	9/18, pgs. 52–53
episodes, self-criticism, suicidal ideation, and depressive	37. This accelerated biological aging could contribute to
symptoms.	increased and age-related diseases observed in
A. Expressive writing	patients with depression.
B. Journaling	A. Falls
C. Autobiographical Self-Enhancement Training (ASET)	B. Mortality
D. All 3 interventions	C. Body weight
9/18, pg. 51	D. All of the above
	9/18, pgs. 52–53
33. In a post-study evaluation of treatment satisfaction,	******
patient ratings indicated that this intervention was the	
least enjoyable:	38. Research has shown that mental health smartphone
A. Expressive writing	apps can be useful in clinical samples of patients with
A. Expressive writing	
	emotional problems. A new study found the interventions
B. ASET	also improve wellbeing in a nonclinical population.
B. ASET C. Journaling	also improve wellbeing in a nonclinical population.  A. True
B. ASET	also improve wellbeing in a nonclinical population.

4 CME / Exam 14

39. In the study, all 3 self-guided CBT-based apps—	44. In this study, the rate of suicide was increased:						
MoodPrism, MoodMission, and MoodKit—produced	A. With increasing TBI severity						
significant improvements from baseline in depression and anxiety scores. However, when compared with a control	B. As a function of the number of days in treatment for TBI						
group, only was significantly more effective at	C. Within the first 6 months after injury						
reducing anxiety.	D. All of the above						
A. MoodPrism							
B. MoodMission	10/18, pgs. 56–57						
C. MoodKit							
D. None of the above	45. Suicide risk was found to be increased across all						
9/18, pgs. 53–54	severity levels of TBI, including mild injuries.						
********	A. True						
40. In a naturalistic study of a highly accelerated 4-day exposure and response prevention (ERP) protocol in 90 patients with moderate-to-severe OCD,% of	B. False 10/18, pgs. 56–57 ************************************						
patients completed treatment.							
A. 64	46. In a small controlled trial in pregnant women, repeti-						
B. 76	tive transcranial magnetic stimulation (rTMS) reduced						
C. 89	symptoms of depression following treatment during the						
D. 100	trimester(s).						
10/18, pgs. 55–56	A. First						
10/10, pgs. 33	B. Second						
41. Study patients experienced a significant reduction in	C. Second and third						
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score,	D. Third						
from a pre-treatment mean of 26 to 10.5 after the ERP	10/10 mag 57 50						
protocol. At 3-month follow-up, the mean Y-BOCS was:	10/18, pgs. 57–58						
A. 10.7							
B. 11.9	47. No treatment-related changes in estradiol or proges-						
C. 15.2	terone levels were observed in women who received rTMS						
D. 19.5	nor were there any clinically relevant cognitive changes.						
10/18, pgs. 55–56	A. True						
10/10, pgs. 33-30	B. False						
42. In this study, results in subgroup analysis of	10/19 = 57 59						
patients with moderate or severe symptoms.	10/18, pg. 57–58						
A. Differed	********						
B. Did not differ							
10/19 pag 55 56	48. An uncontrolled study was undertaken in patients with						
10/18, pgs. 55–56  ********	noncombat PTSD to test the efficacy of cognitive behavioral therapy (CBT) plus heart rate variability						
43. In a Danish population-based study with a dataset of more than 7.4-million persons, the absolute rate of suicide in those with traumatic brain injury (TBI) was about that of the population with no TBI.  A. Half	biofeedback. The therapy was divided into distinct modules that taught basic core skills and addressed common PTSD symptoms. The heart rate variability biofeedback was incorporated into the module.  A. Nightmare						
B. Twice	B. Dissociation						
	C. Hyperarousal and reactivity						
C. 3 times	D. Avoidance						
D. 4 times							
10/18, pgs. 56–57	10/18, pgs. 58–59						

CME / Exam 14 5

49. Of 30 patients enrolled in the study, 26:	55. According to data extracted from multiple pharmacogenetic information hubs, the majority of gene/drug interactions in psychiatry involve:  A. Xanthine oxidase B. Uridine glucuronyl transferases C. P-glycoprotein D. The cytochrome P450 enzymes 2D6 and 2C19						
A. Completed the protocol							
B. Achieved remission							
C. Experienced adverse events							
D. Completed the protocol and achieved remission							
10/18, pgs. 58–59							
*********	D. The cytochrome P450 enzymes 2D6 and 2C19						
	11/18, pgs. 62–63						
50. The habenula, a small brain structure, interfaces with the basal ganglia and limbic system and connects with the neurotransmitter system(s).	56. A minimum standard genetic panel was recently proposed for pharmacogenetic testing in psychiatry. While						
A. Dopaminergic	there is currently no consensus on which patients will						
B. Serotonergic	require testing or when, it will likely be most useful in						
C. Noradrenergic	and those who have not benefitted from previous						
D. All of the above	medication.						
10/18, pgs. 59–60	A. The elderly						
.10	B. Very young children						
51. In a large sample of psychiatric inpatients, MRI studies of structural and functional habenular connectivity on admission predictive of response to	C. Patients experiencing a high adverse-effect burden D. Men who will not participate in psychotherapy						
depression treatment.	11/18, pgs. 62–63						
A. Were	******						
B. Were not							
10/18, pgs. 59–60 ********	57. The 23andMe Personal Genome Service Pharmacogenetic Reports test is now FDA approved for direct-to-consumer sale. According to the FDA, these tests						
52. In a large sample of patients with highly refractory depression, adjunctive vagus nerve stimulation (VNS) improved quality of life, but only in patients who met the conventional definition of depression response.	do not, and results should be used to inform patient-physician discussions.  A. Diagnose medical conditions  B. Determine which medications are appropriate						
A. True	C. Provide medical advice						
B. False	D. All of the above						
11/18, pgs. 61–62	11/18, pg. 63						
53. In the study, adjunctive VNS produced significantly greater improvement in all of the following quality of life domains <i>except</i> :	*************************************						
A. Mood	58. Photobiomodulation (PBM) is a low-cost device-based						
B. Economic status	treatment that involves exposing the scalp or peripheral						
C. Leisure activities	tissues to a restricted wavelength of light and can be administered at home. It differs from bright light						
D. Social relationships	therapy by not and not using a broad spectrum						
11/18, pgs. 61–62	of visible light.						
*******	A. Penetrating deep tissue						
	B. Affecting circadian rhythms						
54. Although assays and reporting are becoming more	C. Involving the retina						
uniform, lack of standardization of genetic test panels has	D. All of the above						
been an important obstacle to translating pharmacoge-	11/19 no 64						
netics into standard practice.	11/18, pg. 64						
A. True B. False							

6 CME / Exam 14

11/18, pgs. 62–63

59. According to a literature review, a single session of PBM appears to be safe and to have generally positive antidepressant effects that are Safety of multiple sessions has not been evaluated.	64. According to the MATRICS project, there are 7 domains of cognition that may be impaired in patients with schizophrenia; these include all of the following <i>except</i> :
A. Transient	A. Working memory
B. Long lasting	B. Attention/vigilance
	C. Sensorimotor learning
11/18, pg. 64	D. Problem solving
******	· ·
60. In a group of patients who received psychological treatment for unipolar or bipolar depression or anxiety according to National Institute for Health and Care Excellence recommendations, levels of cortisol in were predictive of treatment response.  A. Saliva	65. In 2 controlled trials, integrated neurocognitive therapy (INT), which was designed to address these cognitive impairments, improved in patients with schizophrenia or schizoaffective disorder.  A. Positive symptoms
B. Hair	B. Negative symptoms only
C. Blood	C. Global function only
D. None of the above	D. Both negative symptoms and global function
11/18, pgs. 64–65	12/18, pgs. 67–68
61. In the study, compared with patients who achieved response, those whose depression or anxiety did not respond to psychotherapy had levels of cortisol.  A. Lower B. Higher  11/18, pgs. 64–65  62. Because it is assumed that early parental behavior toward offspring can affect HPA-axis reactivity, childhood trauma was also assessed as a potential predictor of response in the study. Hair cortisol levels were significantly associated with childhood trauma.  A. True B. False  11/18, pgs. 64–65	66. The Personalized Prognostic Tools for Early Psychosis Management is an ongoing study that aims to develop prognostic signatures for poor functional outcomes in groups at risk for psychosis. In the study, 3 models (i.e., neuroimaging, clinical, combined) were compared for their accuracy at predicting poor functional outcomes in patients at clinical high risk for psychosis or with recentonset depression. Which model was found to have the greatest accuracy?  A. The clinical model  B. The neuroimaging model  C. The combined model  12/18, pg. 68  67. Given the high cost of MRI, combined prognostics may best be reserved for later in the process or for patients
63. According to the results of a meta-analysis, virtual reality exposure therapy (VRET) was more effective than waitlist and psychological control conditions at reducing in patients with a range of anxiety and related disorders.	whose predicted clinical course is more ambiguous.  A. True B. False  12/18, pg. 68
A. General subjective and disorder-specific distress	
B. Behavioral and cognitive outcomes	68. The reSET-O cognitive behavioral therapy program
C. Psychophysiological outcomes	in patients with opioid use disorder.
D. All of the above	A. Decreased illicit drug use
11/18, pgs. 65–66	<ul><li>B. Increased treatment retention</li><li>C. Decreased drug use and increased treatment retention</li></ul>
خوري في	D. None of the above
	12/18, pg. 69

CME / Exam 14 7

designed to be used as a stand-alone substitute for pharmacotherapy.	consensus statement on diagnosing and treating adult ADHD recommends that screening for adult ADHD be					
A. True						
B. False	- ·					
12/18, pg. 69	•					
者亦亦亦亦亦亦亦亦亦亦亦亦	D. All of the above					
70. Behavioral addictions such as are common in patients with bipolar disorder and predict poorer	12/18, pg. 71					
outcomes and a more severe illness course.	74. Whether late-onset ADHD exists is controversial, and					
A. Pathological gambling	many individuals in whom onset appears to be late likely					
B. Kleptomania						
C. Compulsive sexual behavior						
D. All of the above	B. False					
12/18, pgs. 69–70	12/18, pg. 71					
	ADHD recommends that screening for adult ADHD be offered to individuals with:  A. Chronic inattention, restlessness, or impulsivity B. Emotional instability C. A history of behavioral problems D. All of the above  12/18, pg. 71  74. Whether late-onset ADHD exists is controversial, and many individuals in whom onset appears to be late likely met full criteria at some time during childhood. A. True B. False					
71. The only treatment currently approved specifically to treat bipolar disorder and behavioral addiction together is:  A. Lithium  B. Cognitive behavioral therapy  C. ECT	Clinical Psychopharmacology regarding physician experience with e-prescribing, about of respondents					
D. There is no approved treatment	Clinical Psychopharmacology regarding physician experience with e-prescribing, about of respondents believe the e-prescribing system produced incorrect warnings regarding dosing ranges, drug interactions, contraindications, or other matters.  A. One-quarter					
12/18, pgs. 69–70	A. One-quarter					
********	B. One-third					
	C. One-half					
72. According to a review of complementary medicine	D. Three-quarters					
approaches to depression and/or anxiety in the antenatal period, limited evidence suggests that acupuncture,						
, mindfulness training, and massage may be useful.	水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水水					
A. Bright light therapy						
B. Yoga						
C. Omega-3 fatty acids						
D. All of the above						
12/18, pgs. 70–71						
***********						

8 CME / Exam 14

## M.J. Powers & Co. Continuing Education

### Psychiatry Alerts NOS - Activity Evaluation Form

Please note: Credit letters will be issued upon receipt of this completed evaluation form. The planning and execution of useful and educationally sound continuing education activities are guided in large part by input from participants. To assist us in evaluating the effectiveness of this activity, please complete this evaluation form. Your response will help ensure that future programs are informative and meet the educational needs of all participants. Thank you for your cooperation!

Program Objectives:	Stro Agr	ngly	Strongly Disagree			
Having completed this activity, you are better able to:	71g	icc		D156	igicc	
Recognize and implement new diagnostic and treatment approaches for	psychiatric disorders.	5	4	3	2	1
Determine appropriate treatment selection for various psychiatric disord	5	4	3	2	1	
Identify and appropriately prescribe nonpharmacological therapeutic interpsychiatric disorders.	terventions for various	5	4	3	2	1
Determine appropriate patient evaluation and treatment selection for va disorders.	rious psychiatric	5	4	3	2	1
Overall Evaluation:	Strongly Agree			Strongly Disagree		
The information presented increased my awareness/understanding of the	e subject.	5	4	3	2	1
The information presented will influence how I practice.		5	4	3	2	1
The information presented will help me improve patient care.		5	4	3	2	1
The information demonstrated current knowledge of the subject.		5	4	3	2	1
The program was educationally sound and scientifically balanced.		5	4	3	2	1
The program avoided commercial bias or influence.		5	4	3	2	1
Overall, the program met my expectations.		5	4	3	2	1
Based on information presented in the program, I will (please check one):						
☐ Seek additional information on this topic. ☐ De	hange my practice. o nothing as current prac ogram's recommendatio		eflec	ts		
If you anticipate changing one or more aspects of your practice as a resu us with a brief description of how you plan to do so:				-	pleas	e provide
Please provide any additional comments pertaining to this activity and s	uggestions for improven	nent:_				
Please list any topics that you would like to be addressed in future educa	ntional activities:					

# Answer Sheet

### **PSYCHIATRY ALERTS NOS**

45 Carey Ave, Ste. 111, Butler, NJ 07405 E-mail: cme@alertpubs.com Fax: 973-898-1201

Activity	Code:	18MP02N	Test 14

e-mail address (for credit notification)

	A	В	$\mathbf{C}$	D		A	В	$\mathbf{C}$	D			A	A B	A B C
1	A	B	©	D	26	A	B	©	<b>D</b>	51		A	A B	A B C
2	A	$^{lack}$	©	D	27	A	$^{lack}$	©	D	52		A	A B	A B C
3	A	B	©	D	28	A	B	©	D	53		A	A B	A B C
4	A	lacksquare	©	D	29	A	lacksquare	©	<b>(D)</b>	54		A	A B	A B C
5	A	B	©	D	30	A	B	©	<b>D</b>	55	Œ	D	B	() (B) (C)
6	A	lacksquare	©	D	31	A	B	©	<b>(D)</b>	56	A	)	B	) B C
7	A	B	©	D	32	A	B	©	<b>D</b>	57	A		B	B C
8	A	$^{lack}$	©	D	33	A	lacksquare	©	<b>(D)</b>	58	A		B	B ©
9	A	B	©	D	34	A	B	©	<b>D</b>	59	A		B	B C
10	A	$^{lack}$	©	D	35	A	lacksquare	©	<b>(D)</b>	60	A		B	B ©
11	A	B	©	D	36	A	B	©	<b>D</b>	61	A		B	B ©
12	A	$^{lack}$	©	<b>(D)</b>	37	A	lacksquare	©	<b>(D)</b>	62	A		$^{lack}$	B ©
13	A	B	©	D	38	A	B	©	D	63	A		B	B ©
14	A	$^{lack}$	©	D	39	A	$^{lack}$	©	<b>(D)</b>	64	A		B	B ©
15	A	B	©	D	40	A	B	©	D	65	A		B	B ©
16	A	$^{lack}$	©	D	41	A	$^{lack}$	©	<b>(D)</b>	66	A		$^{lack}$	B ©
17	A	B	©	D	42	A	B	©	D	67	A		B	BC
18	A	$^{lack}$	©	D	43	A	lacksquare	©	D	68	A		$^{lack}$	B ©
19	A	B	©	D	44	A	B	©	<b>D</b>	69	A		B	B C
20	A	$^{lack}$	©	D	45	A	B	©	D	70	A		B	B ©
21	A	B	©	D	46	A	B	©	<b>D</b>	71	A		B	B C
22	A	B	©	<b>(D)</b>	47	A	B	©	<b>(D)</b>	72	A		B	B ©
23	A	B	©	D	48	A	B	©	D	73	A		B	B C
24	A	B	©	D	49	A	B	©	<b>(D)</b>	74	A		B	B ©
25	A	B	©	D	50	A	B	©	<b>D</b>	75	A		B	B C

I attest that I have completed the Psychiatry Alerts NOS activity as design	ed.
---	-----

☐ Physicians: I claim AMA PRA Cates	gory 1 Credit(s) <sup>TM</sup> for participating in this activity (1 credit for each hour
of participation, not to exceed 12 credits).	
□ Non-Physicians: I claim (up to 1.2) contact hours of instruction.	Continuing Education Units (CEUs). One CEU is awarded for 10
Signature	Date
Exam must be returned by June 30, 2020	CME Activity Code: 18MP02N Test 14